Answers are grounded in this paper and cite their sources.
BACKGROUND: Connective tissue growth factor (CTGF) has been identified as a key factor in the pathogenesis of diseases with significant fibrosis-related complications such as hepatitis, diabetes and renal transplantation. Increasing evidence shows that CTGF levels in plasma, serum and urine have promising biomarker applicability in these disorders. OBJECTIVE: To present an overview of current knowledge on CTGF in various patient populations and the technical aspects of CTGF measurement by enzyme-linked immunosorbent assay (ELISA). METHOD: We performed a comprehensive literature search by using electronic bibliographic databases. CONCLUSION: CTGF is associated with disease severity parameters and outcome in fibrotic disease and may have diagnostic and prognostic values. However, CTGF ELISA needs standardization.
No takes yet. Share an insight, caveat, or question.
Dendooven et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: